IXHL

Incannex Healthcare Inc. (IXHL) | Rumor.io

Incannex Healthcare

IXHL

Attention (50-day avg)0.01%

Attention rank (50-day avg)#651

Bullish sentiment (50-day avg)81%

Price to earnings ratio-0.08

Market capitalization39.5M

Earnings per share-1.66

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about IXHL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% 0	0.01% 0	0.01% +0	0.04% -0.07

Sep 29

The author believes that Incannex Healthcare Limited ($IXHL) has the potential for a favourable result due to its stronger balance sheet and share count, despite recent setbacks and delays.
The company's biotech sector and pharmaceutical industry experience have made the author more knowledgeable and optimistic about its future, with the potential for explosive growth.
The author is concerned about the lack of transparency regarding the FDA discussions and Phase 3 pathway for Incannex Healthcare Limited, which may indicate deliberate silence or behind-the-scenes work.

Generated by AI

Sentiment

Of the messages about IXHL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	90% +8.37	74.8% -7.71	79.34% -2.83	81.36% -0.99
Bearish	10% -8.37	25.2% +7.71	20.66% +2.83	18.64% +0.99

Bullish· Sep 16

The company's share price has shown significant action, with a strong close and potential for further growth.
The company's stock price is undervalued, with a potential 10-fold increase in value, considering its cash reserves, three drugs in development, and one drug on track for phase 3 with fast track designation.
The company's stock price has shown a nice trajectory, and if it can hold the current level, it may continue to rise, potentially leading to a big dump if news is released.

Bearish· Jun 23

Incannex Healthcare Limited's market capitalization may fall below $35M, potentially triggering a warning notice from the authorities.
The company's management style has been criticized as amateurish and shifty, with allegations of insider trading, fake accounts, and a large social media shilling network.
The stock's low volume and lack of communication from management have led to a loss of trust, which is reflected in the company's low stock price.

Generated by AI

Topics

Of the messages about IXHL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	53.85%	75.93%	30.22%
Technical Analysis	—	46.15%	24.07%	46.28%
Macro	—	0%	0%	7.51%
Controversies	—	0%	0%	0.73%
Analysts	—	0%	0%	14.65%
Earnings	—	0%	0%	0.61%

Earnings· Aug 7

$IXHL Incannex Healthcare Limited beat earnings expectations, with revenue and EPS beating forecasts and losses narrowing.
The company's healthier margins and operational improvement suggest potential upside momentum.
Analyst sentiment may shift to a more positive outlook following the better-than-expected Q2 performance.

Announcements· Mar 27

Incannex Healthcare Limited ($IXHL) has reactivated its share repurchase program, citing a significant disconnect between its market valuation and financial strength.
The company has executed repurchases over the past two trading days, reflecting its confidence in its valuation and strategic position.
Incannex has approximately $75M in cash and no debt, with $18.5M remaining available for repurchases as of December 31, 2025.

Technical Analysis· Mar 25

$IXHL is trading in a constructive setup, with a potential break above $3.40 flipping the trend bullish and setting a target of $4.
The stock has shown signs of life after a brutal downtrend, with a +20% move on news and a clean bottom bounce setup on the daily chart, suggesting a rebound is possible.
$IXHL is currently pinned between $2.78 support and $3.39 resistance, with a close above $3.39 clearing the final technical hurdle to the 50-day MA at $6.96.

Generated by AI

Community

Of the messages about IXHL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	97.87%	97.65%	98.81%	79.46%
Newcomers	2.13%	2.35%	1.19%	20.54%

Regulars· Sep 29

The author believes that the chart for IXHL will suddenly come alive again, referencing the company's past results and the potential for a favourable outcome.
The author sees IXHL as a company that's been further de-risked, with a stronger balance sheet and a share count that could make a positive result explosive, despite bears seeing failure or delisting.
The author notes that IXHL has a material weakness in its internal controls over financial reporting, which could have a material adverse effect on the stock price, and questions whether institutional ownership will improve meaningfully.

Newcomers· Mar 25

New investors are focused on Incannex Healthcare's (IXHL) partnership with AASM Foundation, which they believe will have a noticeably positive impact on the stock.
Some newcomers are scaling into a position in IXHL, seeing potential for a larger move after a recent positive Phase 2 data release for IHL-42X.
Other investors are focusing on IXHL's technical breakout, with the stock decisively breaching the $3.01 resistance level and showing signs of life after a brutal downtrend.

Generated by AI

News

Incannex begins Phase 2 dosing study for sleep apnea drug

20d agoInvesting.com

Incannex doses first patient in sleep apnea drug trial

1mo agoInvesting.com

Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X

First patient dosing represents another major clinical milestone for IHL-42X, building on positive Phase 2 RePOSA results demonstrating reductions in AHI...

1mo agoBarchart.com

Incannex Secures A$5.1M R&D Tax Incentive Refund

Detailed price information for Incannex Healthcare Inc ADR (IXHL-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Incannex receives final A$5.1m R&D tax incentive refund

1mo agoInvesting.com

Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea

MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies for high-impact indications,...

2mo agoBarchart.com

Also Discussed

Investors talking about IXHL also mention

#	Name	Attention
1	NuCana plc ADRNCNA	0%new
2	Healthcare Triangle Inc.HCTI	0%0
3	ABP - Abpro Corporation	——
4	AtlasClear Holdings, Inc.ATCH	0.01%0
5	Nvni Group LimitedNVNI	0%0
6	Aspire Biopharma Holdings, Inc.ASBP	0%new
7	Erayak Power Solution Group Inc. Class A Ordinary SharesRAYA	0%0
8	Wang & Lee Group Inc.WLGS	0%0
9	Globavend Holdings LimitedGVH	0%0
10	Intensity Therapeutics, Inc.INTS	0%0

Incannex Healthcare Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company focused on developing oral combination medicines and psychedelic-based therapies for chronic conditions with limited treatment options. Incannex Healthcare Inc. is currently advancing programs in obstructive sleep apnea, generalized anxiety disorder, rheumatoid arthritis, and inflammatory disorders through its research and development of cannabinoid and psychedelic pharmaceutical products. Its pipeline includes fixed-dose and synthetic oral treatments designed to target underlying biological pathways and support clinical development across sleep medicine, mental health, and inflammation. Based in Sydney, Australia, Incannex Healthcare Inc. operates as a science-led developer of novel therapeutics aimed at addressing significant unmet medical needs in modern healthcare.

Website

Location

8 Century Circuit

Sydney, NSW, 2153

Australia

Social

What share of all stock conversation is about IXHL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% 0	0.01% 0	0.01% +0	0.04% -0.07

Sep 29

The author believes that Incannex Healthcare Limited ($IXHL) has the potential for a favourable result due to its stronger balance sheet and share count, despite recent setbacks and delays.
The company's biotech sector and pharmaceutical industry experience have made the author more knowledgeable and optimistic about its future, with the potential for explosive growth.
The author is concerned about the lack of transparency regarding the FDA discussions and Phase 3 pathway for Incannex Healthcare Limited, which may indicate deliberate silence or behind-the-scenes work.

Generated by AI

Sentiment

Of the messages about IXHL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	90% +8.37	74.8% -7.71	79.34% -2.83	81.36% -0.99
Bearish	10% -8.37	25.2% +7.71	20.66% +2.83	18.64% +0.99

Bullish· Sep 16

The company's share price has shown significant action, with a strong close and potential for further growth.
The company's stock price is undervalued, with a potential 10-fold increase in value, considering its cash reserves, three drugs in development, and one drug on track for phase 3 with fast track designation.
The company's stock price has shown a nice trajectory, and if it can hold the current level, it may continue to rise, potentially leading to a big dump if news is released.

Bearish· Jun 23

Incannex Healthcare Limited's market capitalization may fall below $35M, potentially triggering a warning notice from the authorities.
The company's management style has been criticized as amateurish and shifty, with allegations of insider trading, fake accounts, and a large social media shilling network.
The stock's low volume and lack of communication from management have led to a loss of trust, which is reflected in the company's low stock price.

Generated by AI

Topics

Of the messages about IXHL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	53.85%	75.93%	30.22%
Technical Analysis	—	46.15%	24.07%	46.28%
Macro	—	0%	0%	7.51%
Controversies	—	0%	0%	0.73%
Analysts	—	0%	0%	14.65%
Earnings	—	0%	0%	0.61%

Earnings· Aug 7

$IXHL Incannex Healthcare Limited beat earnings expectations, with revenue and EPS beating forecasts and losses narrowing.
The company's healthier margins and operational improvement suggest potential upside momentum.
Analyst sentiment may shift to a more positive outlook following the better-than-expected Q2 performance.

Announcements· Mar 27

Incannex Healthcare Limited ($IXHL) has reactivated its share repurchase program, citing a significant disconnect between its market valuation and financial strength.
The company has executed repurchases over the past two trading days, reflecting its confidence in its valuation and strategic position.
Incannex has approximately $75M in cash and no debt, with $18.5M remaining available for repurchases as of December 31, 2025.

Technical Analysis· Mar 25

$IXHL is trading in a constructive setup, with a potential break above $3.40 flipping the trend bullish and setting a target of $4.
The stock has shown signs of life after a brutal downtrend, with a +20% move on news and a clean bottom bounce setup on the daily chart, suggesting a rebound is possible.
$IXHL is currently pinned between $2.78 support and $3.39 resistance, with a close above $3.39 clearing the final technical hurdle to the 50-day MA at $6.96.

Generated by AI

Community

Of the messages about IXHL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	97.87%	97.65%	98.81%	79.46%
Newcomers	2.13%	2.35%	1.19%	20.54%

Regulars· Sep 29

The author believes that the chart for IXHL will suddenly come alive again, referencing the company's past results and the potential for a favourable outcome.
The author sees IXHL as a company that's been further de-risked, with a stronger balance sheet and a share count that could make a positive result explosive, despite bears seeing failure or delisting.
The author notes that IXHL has a material weakness in its internal controls over financial reporting, which could have a material adverse effect on the stock price, and questions whether institutional ownership will improve meaningfully.

Newcomers· Mar 25

New investors are focused on Incannex Healthcare's (IXHL) partnership with AASM Foundation, which they believe will have a noticeably positive impact on the stock.
Some newcomers are scaling into a position in IXHL, seeing potential for a larger move after a recent positive Phase 2 data release for IHL-42X.
Other investors are focusing on IXHL's technical breakout, with the stock decisively breaching the $3.01 resistance level and showing signs of life after a brutal downtrend.

Generated by AI

Incannex Healthcare

Social

Sep 29

Bullish· Sep 16

Bearish· Jun 23

Earnings· Aug 7

Announcements· Mar 27

Technical Analysis· Mar 25

Regulars· Sep 29

Newcomers· Mar 25

Incannex begins Phase 2 dosing study for sleep apnea drug

Incannex doses first patient in sleep apnea drug trial

Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X

Incannex Secures A$5.1M R&D Tax Incentive Refund

Incannex receives final A$5.1m R&D tax incentive refund

Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea

Also Discussed

Incannex Healthcare Inc.

Company Information

Location

Social

Sep 29

Bullish· Sep 16

Bearish· Jun 23

Earnings· Aug 7

Announcements· Mar 27

Technical Analysis· Mar 25

Regulars· Sep 29

Newcomers· Mar 25

Incannex begins Phase 2 dosing study for sleep apnea drug

Incannex doses first patient in sleep apnea drug trial

Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X

Incannex Secures A$5.1M R&D Tax Incentive Refund

Incannex receives final A$5.1m R&D tax incentive refund

Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea

Also Discussed